BlossomHill Therapeutics reported second-quarter 2026 results while highlighting a substantially strengthened balance sheet following its August initial public offering and encouraging early clinical data from its lead cancer program.
The company completed an upsized IPO after the quarter, selling 10,516,240 shares and generating $168.3 million in gross proceeds. Combined with $95.4 million in cash and cash equivalents held as of June 30, 2026, BlossomHill expects its available resources to fund operations into the second quarter of 2028.
The added capital gives BlossomHill a longer runway as it advances multiple clinical and preclinical programs and prepares for several potential regulatory milestones.
During the second quarter, the company reported a net loss of $23.8 million, or $8.75 per basic and diluted share, compared with a net loss of $13.2 million, or $5.51 per share, a year earlier.
The higher spending largely reflects increased investment in research and development as BlossomHill advances its oncology pipeline.
R&D expenses rose to $21.4 million from $12.5 million, driven by clinical-development activity for the SOLARA trial, IND-enabling work for BH-501284 and additional personnel and facility costs.
General and administrative expenses increased to $3.3 million from $1.6 million.
The increased investment comes alongside encouraging early results for BH-30643, BlossomHill’s treatment candidate targeting advanced or metastatic EGFR C797S-positive non-small cell lung cancer.
The FDA granted Fast Track designation to BH-30643, potentially providing a more streamlined development and regulatory review pathway.
Preliminary results from the SOLARA trial showed a 45% objective response rate and an 88% disease-control rate among patients with C797S resistance.
Those results provide an important early clinical signal as BlossomHill evaluates the program’s potential in patients whose cancers have developed resistance to existing EGFR-targeted therapies.
The company expects to hold an end-of-Phase 1 meeting with the FDA in the fourth quarter of 2026.
BlossomHill is then targeting dosing of the first patient in a pivotal Phase 2 trial during the first quarter of 2027, representing a significant step toward a later-stage development program.
The combination of the recent IPO, Fast Track designation and early SOLARA data puts BlossomHill in a stronger position to continue advancing BH-30643 while investing in the broader pipeline.
With funding expected to extend into 2028, management believes the company has the resources to pursue upcoming clinical and regulatory milestones without an immediate need to return to the capital markets.
KEY QUOTES:
“With a strong balance sheet following our successful initial public offering in August, we believe we are well positioned to deliver important clinical and regulatory milestones over the coming quarters as we continue advancing our intentionally designed medicines that address significant unmet medical needs in cancer treatment.”
Jean Cui, Ph.D., Founder, President and CEO of BlossomHill Therapeutics
